What is claimed is:

1. A compound according to the formula I:



I

or a stereoisomer, pharmaceutically acceptable salt, ester, or prodrug thereof,

wherein

E is absent or selected from the group consisting of

(1) H,

(2) substituted or unsubstituted C_1-C_6-alkyl,

(3) substituted or unsubstituted C_2-C_6-alkenyl,

(4) substituted or unsubstituted C_2-C_6-alkynyl,

(5) substituted or unsubstituted aryl,

(6) substituted or unsubstituted heterocyclyl, and

(7) substituted or unsubstituted heteroaryl;

L is absent or selected from the group consisting of

(1) substituted or unsubstituted C_1-C_6-alkyl,

(2) $-(NH)_{0-1}-(CH_2)_j-NR^{3L}-(CH_2)_k-$,

(3) $-(NH)_{0-1}-C(R^{1L}, R^{2L})-NR^{3L}-C(R^{1L}, R^{2L})-$,

(4) $-C(R^{1L}, R^{2L})-O-C(R^{1L}, R^{2L})-$,

(5) $-(CH_2)_j-NR^{3L}-C(R^{1L}, R^{2L})-CONH-(CH_2)_k-$,

(6) $-CO-C(R^{1L}, R^{2L})-NHCO-$,

(7) $-CONH-$,

(8) $-NHCO-$,

wherein

R^{1L}, R^{2L}, and R^{3L} are independently selected from the group consisting of

(a) H,

(b) substituted or unsubstituted C_1-C_6-alkyl,

(c) C_1-C_6-alkyl substituted with aryl,

(d) C_1-C_6-alkyl substituted with heterocyclyl, and

(e) C_1-C_6-alkyl substituted with heteroaryl,

or R^{1L} and R^{3L}, together with the atoms to which they are attached can form a substituted or unsubstituted heterocyclic ring, having from 3 to 8 ring atoms, wherein 1-2 ring atoms of the heterocyclic ring system are selected from N, O and S,

j is an integer of 0-4;

k is an integer of 0-4;

D is absent or selected from the group consisting of

(1) substituted or unsubstituted C_3-C_8-cycloalkyl,

(2) substituted or unsubstituted aryl,

(3) substituted or unsubstituted heterocyclyl, and

(4) substituted or unsubstituted heteroaryl;

G is absent or selected from the group consisting of

(1) $-(CH_2)_i-O-(CH_2)_i-$,

(2) $-(CH_2)_i-S-(CH_2)_i-$,

(3) $-(CH_2)_i-NR^g-(CH_2)_i-$,

(4) $-C(=O)-$,

(5) $-NHC(=O)-$,

(6) $-C(=O)NH-$,

(7) $-(CH_2)_iNHCH_2C(=O)NH-$,

(8) $-C\equiv C-$,

(9) $-C\equiv C-C\equiv C-$, and

(10) $-C=C-$;

wherein

R^g is H or substituted or unsubstituted C_1-C_6-alkyl;

i is an interger of 0-4;

Y is selected from the group consisting of

(1) substituted or unsubstituted C_3-C_8-cycloalkyl,

(2) substituted or unsubstituted aryl,

(3) substituted or unsubstituted heterocyclyl, and

(4) substituted or unsubstituted heteroaryl;

X is selected from the group consisting of

(1) $-(C=O)-$,

(2) $-C_1$-C_6-alkyl$-(C=O)-$,

(3) $-C_2$-C_6-alkenyl$-(C=O)-$,

(4) $-C_2$-C_6-alkynyl-(C=O)-, and

(5) $-CH_2-$;

or when B is absent, X and A, together with the atoms to which they are attached can form a heterocyclic ring, having from 5 to 8 ring atoms, wherein 1-2 ring atoms of the heterocyclic ring system are selected from N, O and S;

B is a absent or



wherein R^{1b} and R^{2b}, are independently selected from the group consisting of

(a) H,

(b) substituted or unsubstituted C_1-C_6-alkyl,

(c) substituted or unsubstituted C_2-C_6-alkenyl,

(d) substituted or unsubstituted C_2-C_6-alkynyl,

(e) substituted or unsubstituted aryl,

(f) substituted or unsubstituted heterocyclyl,

(g) substituted or unsubstituted heteroaryl,

(h) C_1-C_6-alkyl substituted with aryl,

(i) C_1-C_6-alkyl substituted with heterocyclyl, and

(j) C_1-C_6-alkyl substituted with heteroaryl,

or R^{1b} and R^{2b}, together with the atoms to which they are attached can form a substituted or unsubstituted heterocyclic ring, having from 3 to 8 ring atoms, wherein 1-2 ring atoms of the heterocyclic ring system are selected from N, O and S;

q is an integer of 0-4;

R_3 is H or substituted or unsubstituted C_1-C_6-alkyl,

or R_3 and A, together with the atoms to which they are attached can form a substituted or unsubstituted 3-10 membered cycloalkyl or a heterocyclic ring system, wherein the heterocyclic ring system may have from 3 to 10 ring atoms, with 1 to 2 rings being in the ring system and contain from 1-4 heteroatoms selected from N, O and S;

R_4 is H or substituted or unsubstituted C_1-C_6-alkyl,

or R_4 and A, together with the atoms to which they are attached can form a substituted or unsubstituted heterocyclic ring, having from 3 to 8 ring atoms, wherein 1-2 ring atoms of the heterocyclic ring system are selected from N, O and S;

n is an integer of 0-2;

A is selected from the group consisting of

(1) H,

(2) $-(CH_2)_rC(R^{1a}, R^{2a})(CH_2)_sOR^{3a}$,

(3) $-(CH_2)_rC(R^{1a}, R^{2a})N(R^{4a}, R^{5a})$,

(4) $-(CH_2)_rC(R^{1a}, R^{2a})N(R^{4a})COR^{3a}$,

(5) $-(CH_2)_rC(R^{1a}, R^{2a})NHCON(R^{4a}, R^{5a})$,

(6) $-(CH_2)_rC(R^{1a}, R^{2a})NHC(=NH)N(R^{4a}, R^{5a})$,

(7) $-CH(R^{1a}, R^{2a})$,

(8) $-C\equiv CH$,

(9) $-(CH_2)_rC(R^{1a}, R^{2a})CN$,

(10) $-(CH_2)_rC(R^{1a}, R^{2a})CO_2R^{3a}$, and

(11) $-(CH_2)_rC(R^{1a}, R^{2a})CN(R^{4a}, R^{5a})$,

wherein R^{1a}, R^{2a}, R^{3a}, R^{4a}, and R^{5a} are independently selected from the group consisting of

(a) H,

(b) substituted or unsubstituted C_1-C_6-alkyl,

(c) substituted or unsubstituted aryl,

(d) substituted or unsubstituted heterocyclyl,

(e) substituted or unsubstituted heteroaryl,

(f) C_1-C_6-alkyl substituted with aryl,

(g) C_1-C_6-alkyl substituted with heterocyclyl, and

(h) C_1-C_6-alkyl substituted with heteroaryl,

or R^{4a} and R^{5a} together with the N atom to which they are attached can form a substituted or unsubstituted heterocyclic ring, having from 3 to 8 ring atoms, wherein 1-2 ring atoms of the heterocyclic ring system are selected from N, O and S;

r is an integer of 0-4;

s is an integer of 0-4;

Q is absent or selected from the group consisting of

(1) $-C(=O)N(R_1, R_2)$,

(2) $-NHC(=O)N(R_1, R_2)$,

(3) $-N(OH)C(=O)N(R_1, R_2)$,

(4) $-CH(OH)C(=O)N(R_1, R_2)$,

(5) $-CH[N(R^{2q}, R^{3q})]C(=O)N(R_1, R_2)$,

(6) $-CHR^{1q}C(=O)N(R_1, R_2)$,

(7) $-CO_2H$,

(8) $-C(=O)NHSO_2R^{4q}$,

(9) $-SO_2NH_2$,

(10) $-N(OH)C(=O)R^{1q}$,

(11) $-N(OH)SO_2R^{4q}$,

(12) $-NHSO_2R^{4q}$,

(13) $-SH$,

(14) $-CH(SH)(CH_2)_{0-1}C(=O)N(R_1, R_2)$,

(15) $-CH(SH)(CH_2)_{0-1}CO_2H$,

(16) $-CH(OH)(CH_2)_{0-1}CO_2H$,

(17) $-CH(SH)CH_2CO_2R^{1q}$,

(18) $-CH(OH)(CH_2)SO_2NH_2$,

(19) $-CH(CH_2SH)NHCOR^{1q}$,

(20) $-CH(CH_2SH)NHSO_2R^{4q}$,

(21) $-CH(CH_2SR^{5q})CO_2H$,

(22) $-CH(CH_2SH)NHSO_2NH_2$,

(23) $-CH(CH_2OH)CO_2H$,

(24) $-CH(CH_2OH)NHSO_2NH_2$,

(25) $-C(=O)CH_2CO_2H$,

(26) $-C(=O)(CH_2)_{0-1}CONH_2$,

(27) $-OSO_2NHR^{5q}$,

(28) $-SO_2NHNH_2$,

(29) $-P(=O)(OH)_2$,

(30) 

(31)  , and

(32)  ;

R_1 is selected from the group consisting of

(1) $-H$,

(2) $-OH$,

(3) $-OC_{1-6}$-alkyl,

(4) $-N(R^{2q}, R^{3q})$, and

(5) substituted or unsubstituted C_{1-6}-alkyl;

R_2 is selected from the group consisting of

(1) H,

(2) substituted or unsubstituted C_1-C_6-alkyl,

(3) substituted or unsubstituted C_2-C_6-alkenyl,

(4) substituted or unsubstituted C_2-C_6-alkenyl,

(5) substituted or unsubstituted aryl,

(6) substituted or unsubstituted heterocyclyl,

(7) substituted or unsubstituted heteroaryl,

(8) C_1-C_6-alkyl substituted with aryl,

(9) C_1-C_6-alkyl substituted with heterocyclyl, and

(10) C_1-C_6-alkyl substituted with heteroaryl,

or R^1 and R^2, together with the N atom to which they are attached can form a substituted or unsubstituted heterocyclic ring, having from 3 to 10 ring atoms, wherein 1-4 ring atoms of the heterocyclic ring system are selected from N, O and S,

R^{1q}, R^{2q}, R^{3q}, R^{4q}, and R^{5q} are selected from H or C_1-C_6 alkyl,

wherein B is absent, or E, L, G, and B are absent, or E, L, and G are absent, or E, L, and B are absent, or E, L, D, G, and B are absent.

2. A compound of claim 1, wherein

wherein

E is absent or selected from the group consisting of

(1) H,

(2) substituted or unsubstituted C_1-C_6-alkyl,

(3) substituted or unsubstituted aryl,

(4) substituted or unsubstituted heterocyclyl, and

(5) substituted or unsubstituted heteroaryl;

L is absent or selected from the group consisting of

(1) $-(CH_2)_j-NR^{3L}-(CH_2)_k-$,

(2) $-C(R^{1L}, R^{2L})_j-NR^{3L}-C(R^{1L}, R^{2L})_k-$,

(3) $-C(R^{1L}, R^{2L})_j-O-C(R^{1L}, R^{2L})_k-$,

(4) $-(CH_2)_j-NR^{3L}-C(R^{1L}, R^{2L})_k-CONH-(CH_2)_k-$,

(5) $-CO-C(R^{1L}, R^{2L})-NHCO-$,

(6) –CONH–, and

(7) –NHCO–,

wherein

R^{1L}, R^{2L}, R^{3L} are independently selected from the group consisting of

(a) H,

(b) substituted or unsubstituted C_1-C_6-alkyl,

(c) C_1-C_6-alkyl substituted with aryl,

(d) C_1-C_6-alkyl substituted with heterocyclyl,

(e) C_1-C_6-alkyl substituted with heteroaryl,

or R^{1L} and R^{3L}, together with the atoms to which they are attached can form a substituted or unsubstituted heterocyclic ring, having from 5 to 8 ring atoms, wherein 1-2 ring atoms of the heterocyclic ring system are selected from N, O and S;

j is an integer of 0-4;

k is an integer of 0-4;

D is absent or selected from the group consisting of

(1) substituted or unsubstituted C_3-C_8-cycloalkyl,

(2) substituted or unsubstituted aryl,

(3) substituted or unsubstituted heterocyclyl,

(4) substituted or unsubstituted heteroaryl, and

G is absent or selected from the group consisting of

(1) –C(=O)–,

(2) –NHC(=O)–,

(3) –C(=O)NH–,

(4) $-(CH_2)_iNHCH_2C(=O)NH-$,

(5) –C≡C–, and

(6) –C≡C—C≡C–,

wherein i is an interger of 0-4;

Y is selected from the group consisting of

(1) substituted or unsubstituted C_3-C_8-cycloalkyl,

(2) substituted or unsubstituted aryl,

(3) substituted or unsubstituted heterocyclyl, and

(4) substituted or unsubstituted heteroaryl;

X is selected from the group consisting of

(1) –(C=O)–,

(2) –C_1-C_6-alkyl–(C=O)–,

(3) –C_2-C_6-alkenyl–(C=O)–,

(4) –C_2-C_6-alkynyl–(C=O)–, and

(5) –CH_2–;

or when B is absent, X and A, together with the atoms to which they are attached can form a heterocyclic ring, having from 5 to 8 ring atoms, wherein 1-2 ring atoms of the heterocyclic ring system are selected from N, O and S;

B is absent or



wherein R^{1b} and R^{2b} are independently selected from the group consisting of

(a) H

(b) substituted or unsubstituted C_1-C_6-alkyl,

(c) substituted or unsubstituted C_2-C_6-alkenyl,

(d) substituted or unsubstituted C_2-C_6-alkenyl,

(e) substituted or unsubstituted aryl,

(f) substituted or unsubstituted heterocyclyl,

(g) substituted or unsubstituted heteroaryl,

(h) C_1-C_6-alkyl substituted with aryl,

(i) C_1-C_6-alkyl substituted with heterocyclyl, and

(j) C_1-C_6-alkyl substituted with heteroaryl,

or R^{1b} and R^{2b}, together with the atoms to which they are attached can form a substituted or unsubstituted heterocyclic ring, having from 5 to 8 ring atoms, wherein 1-2 ring atoms of the heterocyclic ring system are selected from N, O and S;

q is an integer of 0-2;

R_3 is H or substituted or unsubstituted C_1-C_6-alkyl,

or R_3 and A, together with the atoms to which they are attached can form a substituted or unsubstituted 3-10 membered cycloalkyl or a heterocyclic ring system, wherein the heterocyclic ring system may have from 3 to 10 ring atoms, with 1 to 2 rings being in the ring system and contain from 1-4 heteroatoms selected from N, O and S;

R_4 is H or substituted or unsubstituted C_1-C_6-alkyl,

or R_4 and A, together with the atoms to which they are attached can form a substituted or unsubstituted heterocyclic ring, having from 5 to 8 ring atoms, wherein 1-2 ring atoms of the heterocyclic ring system are selected from N, O and S;

A is selected from the group consisting of

(1) H,

(2) $-(CH_2)_rC(R^{1a}, R^{2a})(CH_2)_sOR^{3a}$,

(3) $-(CH_2)_rC(R^{1a}, R^{2a})N(R^{4a}, R^{5a})$,

(4) $-(CH_2)_rC(R^{1a}, R^{2a})N(R^{4a})COR^{3a}$,

(5) $-(CH_2)_rC(R^{1a}, R^{2a})NHCON(R^{4a}, R^{5a})$,

(6) $-(CH_2)_rC(R^{1a}, R^{2a})NHC(=NH)N(R^{4a}, R^{5a})$,

(7) $-CH(R^{1a}, R^{2a})$,

(8) $-C\equiv CH$,

(9) $-(CH_2)_rC(R^{1a}, R^{2a})CN$, and

(10) $-(CH_2)_rC(R^{1a}, R^{2a})CO_2R^{3a}$,

wherein R^{1a}, R^{2a}, R^{3a}, R^{4a}, and R^{5a}, are independently selected from the group consisting of

(a) H,

(b) substituted or unsubstituted C_1-C_6-alkyl,

(c) C_1-C_6-alkyl substituted with aryl,

(d) C_1-C_6-alkyl substituted with heterocyclyl, and

(e) C_1-C_6-alkyl substituted with heteroaryl,

or R^{4a} and R^{5a}, together with the N atom to which they are attached can form a substituted or unsubstituted heterocyclic ring, having from 5 to 8 ring atoms, wherein 1-2 ring atoms of the heterocyclic ring system are selected from N, O and S;

r is an integer of 0-4;

Q is absent or selected from the group consisting of

(1) $-C(=O)N(R_1, R_2)$,

(2) $-NHC(=O)N(R_1, R_2)$,

(3) $-N(OH)C(=O)N(R_1, R_2)$,

(4) $-CH(OH)C(=O)N(R_1, R_2)$,

(5) $-CH[N(R^{2q}, R^{3q})]C(=O)N(R_1, R_2)$, and

(6) $-CHR^{1q}C(=O)N(R_1, R_2)$,

R_1 is selected from the group consisting of

(1) H,

(2) OH,

(3) OC_{1-6}-alkyl,

(4) $N(R^{2q}, R^{3q})$, and

(5) substituted or unsubstituted C_{1-6}-alkyl;

R_2 is selected from the group consisting of

(1) H,

(2) substituted or unsubstituted C_1-C_6-alkyl,

(3) substituted or unsubstituted aryl,

(4) substituted or unsubstituted heterocyclyl,

(5) substituted or unsubstituted heteroaryl,

(6) C_1-C_6-alkyl substituted with aryl,

(7) C_1-C_6-alkyl substituted with heterocyclyl, and

(8) C_1-C_6-alkyl substituted with heteroaryl,

or R^1 and R^2, together with the N atom to which they are attached can form a substituted or unsubstituted heterocyclic ring, having from 3 to 10 ring atoms, wherein 1-4 ring atoms of the heterocyclic ring system are selected from N, O and S,

R^{1q}, R^{2q}, and R^{3q} are selected from H or C_1-C_6 alkyl,

wherein B is absent, or E, L, G, and B are absent, or E, L, and G are absent, or E, L, and B are absent, or E, L, D, G, and B are absent.

3. A compound of claim 1, having the formula II:



II

or a stereoisomer, pharmaceutically acceptable salt, ester, or prodrug thereof, wherein D-G-Y taken together, is selected from the group consisting of











, and



or















wherein

R is selected from the group consisting of $-CH_3$, $-C_2H_5$, $-CH_2OH$, $-OH$, $-OCH_3$, $-OC_2H_5$, $-OCF_3$, $-CN$, $-NO_2$, $-CO_2H$, $-CO_2CH_3$, $-CONH_2$, $-NH_2$, $-F$, $-Cl$, $-Br$, $-CF_3$, $-N(CH_3)_2$, $-NHSO_2CH_3$, and $-NHCOCH_3$;

X is selected from the group consisting of

(1) $-(C=O)-$,

(2) $-C_1$-C_6-alkyl$-(C=O)-$, and

(2) $-C_2$-C_6-alkenyl$-(C=O)-$.

4. A compound of claim I, having the formular III:



III

or a stereoisomer, pharmaceutically acceptable salt, ester, or prodrug thereof, wherein D-G-Y taken together, is selected from the group consisting of







, and

or



wherein

R is selected from the group consisting of $-CH_3$, $-C_2H_5$, $-CH_2OH$, $-OH$, $-OCH_3$, $-OC_2H_5$, $-OCF_3$, $-CN$, $-NO_2$, $-CO_2H$, $-CO_2CH_3$, $-CONH_2$, $-NH_2$, $-F$, $-Cl$, $-Br$, $-CF_3$, $-N(CH_3)_2$, $-NHSO_2CH_3$, and $-NHCOCH_3$;

X is selected from the groups consisting of

(1) $-(C=O)-$,

(2) $-C_1$-C_6-alkyl$-(C=O)-$, and

(3) $-C_2$-C_6-alkenyl$-(C=O)-$.

5. A compound of claim 1, having the formula IV:



IV

or a stereoisomer, pharmaceutically acceptable salt, ester, or prodrug thereof, wherein D-G-Y taken together, is selected from the group consisting of



, and

or



wherein

R is selected from the group consisting of $-CH_3$, $-C_2H_5$, $-CH_2OH$, $-OH$, $-OCH_3$, $-OC_2H_5$, $-OCF_3$, $-CN$, $-NO_2$, $-CO_2H$, $-CO_2CH_3$, $-CONH_2$, $-NH_2$, $-F$, $-Cl$, $-Br$, $-CF_3$, $-N(CH_3)_2$, $-NHSO_2CH_3$, and $-NHCOCH_3$;

X is selected from the groups consisting of

(1) $-(C=O)-$,

(2) $-C_1$-C_6-alkyl$-(C=O)-$, and

(3) $-C_2$-C_6-alkenyl$-(C=O)-$.

6. A compound of claim 1, having the formula V:



V

or a stereoisomer, pharmaceutically acceptable salt, ester, or prodrug thereof, wherein D-G-Y taken together, is selected from the group consisting of



, and

or





wherein

R is selected from the group consisting of $-CH_3$, $-C_2H_5$, $-CH_2OH$, $-OH$, $-OCH_3$, $-OC_2H_5$, $-OCF_3$, $-CN$, $-NO_2$, $-CO_2H$, $-CO_2CH_3$, $-CONH_2$, $-NH_2$, $-F$, $-Cl$, $-Br$, $-CF_3$, $-N(CH_3)_2$, $-NHSO_2CH_3$, and $-NHCOCH_3$;

X is selected from the group consisting of

(1) $-(C=O)-$,

(2) $-C_1$-C_6-alkyl$-(C=O)-$, and

(3) $-C_2$-C_6-alkenyl$-(C=O)-$.

7. A compound of claim 1, having the formula VI:



VI

or a stereoisomer, pharmaceutically acceptable salt, ester, or prodrug thereof, wherein

E is absent or selected from the group consisting of

(1) H,

(2) substituted or unsubstituted C_1-C_6-alkyl,

(3) substituted or unsubstituted aryl,

(4) substituted or unsubstituted heterocyclyl, and

(5) substituted or unsubstituted heteroaryl,

or E and R^{3L}, together with the atoms to which they are attached can form a substituted or unsubstituted heterocyclic ring, having from 3 to 10 ring atoms, wherein 1-4 ring atoms of the heterocyclic ring system are selected from N, O and S,

R^{1L}, R^{3L} are independently selected from the group consisting of

(1) H,

(2) substituted or unsubstituted C_1-C_6-alkyl,

(3) C_1-C_6-alkyl substituted with aryl,

(4) C_1-C_6-alkyl substituted with heterocyclyl, and

(5) C_1-C_6-alkyl substituted with heteroaryl,

or R^{1L} and R^{3L}, together with the atoms to which they are attached can form a substituted or unsubstituted heterocyclic ring, having from 3 to 8 ring atoms, wherein 1-2 ring atoms of the heterocyclic ring system are selected from N, O and S.

8. A compound of claim 1, having the formula VII:



VII

or a stereoisomer, pharmaceutically acceptable salt, ester, or prodrug thereof, wherein

E is absent or selected from the group consisting of

(1) H,

(2) substituted or unsubstituted C_1-C_6-alkyl,

(3) substituted or unsubstituted aryl,

(4) substituted or unsubstituted heterocyclyl, and

(5) substituted or unsubstituted heteroaryl,

or E and R^{3L}, together with the atoms to which they are attached can form a substituted or unsubstituted heterocyclic ring, having from 3 to 10 ring atoms, wherein 1-4 ring atoms of the heterocyclic ring system are selected from N, O and S;

R^{1L}, R^{3L} are independently selected from the group consisting of

(1) H,

(2) substituted or unsubstituted C_1-C_6-alkyl,

(3) C_1-C_6-alkyl substituted with aryl,

(4) C_1-C_6-alkyl substituted with heterocyclyl, and

(5) C_1-C_6-alkyl substituted with heteroaryl,

or R^{1L} and R^{3L}, together with the atoms to which they are attached can form a substituted or unsubstituted heterocyclic ring, having from 3 to 8 ring atoms, wherein 1-2 ring atoms of the heterocyclic ring system are selected from N, O and S.

9. A compound of claim 1, having the formula VIII:



VIII

or a stereoisomer, pharmaceutically acceptable salt, ester, or prodrug thereof, wherein

E is absent or selected from the group consisting of

(1) H,

(2) substituted or unsubstituted C_1-C_6-alkyl,

(3) substituted or unsubstituted aryl,

(4) substituted or unsubstituted heterocyclyl, and

(5) substituted or unsubstituted heteroaryl,

or E and R^{3L}, together with the atoms to which they are attached can form a substituted or unsubstituted heterocyclic ring, having from 3 to 10 ring atoms, wherein 1-4 ring atoms of the heterocyclic ring system are selected from N, O and S;

R^{1L}, R^{3L} are independently selected from the group consisting of

(1) H,

(2) substituted or unsubstituted C_1-C_6-alkyl,

(3) C_1-C_6-alkyl substituted with aryl,

(4) C_1-C_6-alkyl substituted with heterocyclyl, and

(5) C_1-C_6-alkyl substituted with heteroaryl,

or R^{1L} and R^{3L}, together with the atoms to which they are attached can form a substituted or unsubstituted heterocyclic ring, having from 3 to 8 ring atoms, wherein 1-2 ring atoms of the heterocyclic ring system are selected from N, O and S.

10. A compound of claim 1, having the formula IX:



IX

or a stereoisomer, pharmaceutically acceptable salt, ester, or prodrug thereof, wherein

E is absent or selected from the group consisting of

(1) H,

(2) substituted or unsubstituted C_1-C_6-alkyl,

(3) substituted or unsubstituted aryl,

(4) substituted or unsubstituted heterocyclyl, and

(5) substituted or unsubstituted heteroaryl,

or E and R^{3L}, together with the atoms to which they are attached can form a substituted or unsubstituted heterocyclic ring, having from 3 to 10 ring atoms, wherein 1-4 ring atoms of the heterocyclic ring system are selected from N, O and S;

R^{1L}, R^{3L} are independently selected from the group consisting of

(1) H,

(2) substituted or unsubstituted C_1-C_6-alkyl,

(3) C_1-C_6-alkyl substituted with aryl,

(4) C_1-C_6-alkyl substituted with heterocyclyl, and

(5) C_1-C_6-alkyl substituted with heteroaryl,

or R^{1L} and R^{3L}, together with the atoms to which they are attached can form a substituted or unsubstituted heterocyclic ring, having from 3 to 8 ring atoms, wherein 1-2 ring atoms of the heterocyclic ring system are selected from N, O and S.

11. A compound of claim 1, having the formula X:



X

or a stereoisomer, pharmaceutically acceptable salt, ester, or prodrug thereof, wherein

E is absent or selected from the group consisting of

(1) H,

(2) substituted or unsubstituted C_1-C_6-alkyl,

(3) substituted or unsubstituted aryl,

(4) substituted or unsubstituted heterocyclyl, and

(5) substituted or unsubstituted heteroaryl,

or E and R^{3L}, together with the atoms to which they are attached can form a substituted or unsubstituted heterocyclic ring, having from 3 to 10 ring atoms, wherein 1-4 ring atoms of the heterocyclic ring system are selected from N, O and S;

R^{1L}, R^{3L} are independently selected from the group consisting of

(1) H,

(2) substituted or unsubstituted C_1-C_6-alkyl,

(3) C_1-C_6-alkyl substituted with aryl,

(4) C_1-C_6-alkyl substituted with heterocyclyl, and

(5) C_1-C_6-alkyl substituted with heteroaryl,

or R^{1L} and R^{3L}, together with the atoms to which they are attached can form a substituted or unsubstituted heterocyclic ring, having from 3 to 8 ring atoms, wherein 1-2 ring atoms of the heterocyclic ring system are selected from N, O and S.

12. A compound of claim 1, having the formula XI:



XI

or a stereoisomer, pharmaceutically acceptable salt, ester, or prodrug thereof, wherein Y-X taken together, is selected from the group consisting of



, and

13. A compound of claim 1, having the formula XII:



XII

or a stereoisomer, pharmaceutically acceptable salt, ester, or prodrug thereof, wherein R^{1b} and R^{2b} are independently selected from the group consisting of

(1) H,

(2) substituted or unsubstituted C_1-C_6-alkyl,

(3) substituted or unsubstituted C_2-C_6-alkenyl,

(4) substituted or unsubstituted C_2-C_6-alkenyl,

(5) substituted or unsubstituted aryl,

(6) substituted or unsubstituted heterocyclyl,

(7) substituted or unsubstituted heteroaryl,

(8) C_1-C_6-alkyl substituted with aryl,

(9) C_1-C_6-alkyl substituted with heterocyclyl, and

(10) C_1-C_6-alkyl substituted with heteroaryl;

q is an integer of 0-2;

14. A compound of claim 1, having the formula XIII:



XIII

or a stereoisomer, pharmaceutically acceptable salt, ester, or prodrug thereof, wherein R_4 is selected from the group consisting of

(1) H,

(2) substituted or unsubstituted C_1-C_6-alkyl,

(3) C_1-C_6-alkyl substituted with aryl,

(4) C_1-C_6-alkyl substituted with heterocyclyl, and

(5) C_1-C_6-alkyl substituted with heteroaryl;

A is H or –$CH(CH_3)OH$–;

R_1 is H or substituted or unsubstituted C_{1-6}-alkyl;

R_2 is selected from the group consisting of

(1) H,

(2) substituted or unsubstituted C_1-C_6-alkyl,

(3) substituted or unsubstituted aryl,

(4) substituted or unsubstituted heterocyclyl,

(5) substituted or unsubstituted heteroaryl,

(6) C_1-C_6-alkyl substituted with aryl,

(7) C_1-C_6-alkyl substituted with heterocyclyl,

(8) C_1-C_6-alkyl substituted with heteroaryl,

or R^1 and R^2 together with the N atom to which they are attached can form a substituted or unsubstituted heterocyclic ring, having from 3 to 10 ring atoms, wherein 1-2 ring atoms of the heterocyclic ring system are selected from N, O and S.

15. A compound of claim 1, having the formula XIV:



XIV

or a stereoisomer, pharmaceutically acceptable salt, ester, or prodrug thereof, wherein

D-G-Y taken together is selected from the group consisting of














, and


or











wherein

R is selected from the group consisting of $-CH_3$, $-C_2H_5$, $-CH_2OH$, $-OH$, $-OCH_3$, $-OC_2H_5$, $-OCF_3$, $-CN$, $-NO_2$, $-CO_2H$, $-CO_2CH_3$, $-CONH_2$, $-NH_2$, $-F$, $-Cl$, $-Br$, $-CF_3$, $-N(CH_3)_2$, $-NHSO_2CH_3$, and $-NHCOCH_3$;

R_4 is selected from the group consisting of

(1) H,

(2) substituted or unsubstituted C_1-C_6-alkyl,

(3) C_1-C_6-alkyl substituted with aryl,

(4) C_1-C_6-alkyl substituted with heterocyclyl, and

(5) C_1-C_6-alkyl substituted with heteroaryl.

16. A compound of claim 1, having the formula XV:



XV

or a stereoisomer, pharmaceutically acceptable salt, ester, or prodrug thereof, wherein D-G-Y taken together, is selected from the group consisting of



, and



or



wherein

R is selected from the group consisting of $-CH_3$, $-C_2H_5$, $-CH_2OH$, $-OH$, $-OCH_3$, $-OC_2H_5$, $-OCF_3$, $-CN$, $-NO_2$, $-CO_2H$, $-CO_2CH_3$, $-CONH_2$, $-NH_2$, $-F$, $-Cl$, $-Br$, $-CF_3$, $-N(CH_3)_2$, $-NHSO_2CH_3$, and $-NHCOCH_3$;

17. A compound of claim 1, having the formula XVI:



XVI

or a stereoisomer, pharmaceutically acceptable salt, ester, or prodrug thereof, wherein D-G-Y taken together, is selected from the group consisting of



, and

or





wherein

R is selected from the group consisting of $-CH_3$, $-C_2H_5$, $-CH_2OH$, $-OH$, $-OCH_3$, $-OC_2H_5$, $-OCF_3$, $-CN$, $-NO_2$, $-CO_2H$, $-CO_2CH_3$, $-CONH_2$, $-NH_2$, $-F$, $-Cl$, $-Br$, $-CF_3$, $-N(CH_3)_2$, $-NHSO_2CH_3$, and $-NHCOCH_3$;

R_4 is selected from the group consisting of

(1) H,

(2) substituted or unsubstituted C_1-C_6-alkyl,

(3) C_1-C_6-alkyl substituted with aryl,

(4) C_1-C_6-alkyl substituted with heterocyclyl, and

(5) C_1-C_6-alkyl substituted with heteroaryl;

18. A compound of claim 1, having the formula XVII:



XVII

or a stereoisomer, pharmaceutically acceptable salt, ester, or prodrug thereof, wherein

D-G-Y taken together, is selected from the group consisting of



, and

or





wherein

R is selected from the group consisting of $-CH_3$, $-C_2H_5$, $-CH_2OH$, $-OH$, $-OCH_3$, $-OC_2H_5$, $-OCF_3$, $-CN$, $-NO_2$, $-CO_2H$, $-CO_2CH_3$, $-CONH_2$, $-NH_2$, $-F$, $-Cl$, $-Br$, $-CF_3$, $-N(CH_3)_2$, $-NHSO_2CH_3$, and $-NHCOCH_3$.

19. A pharmaceutical composition comprising a compound from one of claims 1 –18 and a pharmaceutically acceptable excipient.

20. A pharmaceutical composition comprising a compound from one of claims 1-18, a second agent, and a pharmaceutically acceptable excipient.

21. A method of treating a patient comprising administering to a patient in need thereof, an effective amount of a compound from one of claims 1-18.

22. A method of treating a patient comprising administering to a patient in need thereof, an effective amount of a compound from one of claims 1-18 and an effective amount of a second agent.

23. A method of treating an infection comprising administering to a patient in need thereof, an effective amount of a compound from one of claims 1-18.

24. A method of treating an infection comprising administering to a patient in need thereof, an effective amount of a compound from one of claims 1-18 and an effective amount of a second agent.